A rising industry giant in semiconductor materials

Meanwhile, growing applications of these materials continue to drive sustained growth in related processing equipment. On the other hand, certain materials—such as silicon, a key consumable in the photovoltaic industry—can serve multiple high-end manufacturing sectors simultaneously. Similarly, specialized filtration membranes are used across new-energy batteries, medical devices, and the semiconductor industry. This has fueled the growth of these high-end composite material segments. Naturally, since demand is largely volume-driven, industry growth rates are not exceptionally high. However, the cross-sector applicability of these materials—and their service to high-margin industries—endows this upstream sector with a notably robust gross margin structure. Overall, the semiconductor materials industry represents one of the most promising long-term growth areas across the entire semiconductor value chain. Indeed, domestic substitution in semiconductor materials has become a highly popular investment theme among A-share investors. II. Entegris: A Company Continuously Consolidating Its Position Returning now to the company itself: today’s Entegris is a firm specializing in semiconductor materials and equipment. Its business is divided into three segments: Semiconductor Chemicals & Equipment Materials (SCEM), Microcontamination Control (MC) equipment, and Advanced Materials Handling (AMH) solutions. Strictly speaking, Entegris is not purely a semiconductor materials company—it also engages in equipment-related businesses, primarily focused on contamination control during storage and transport of raw materials along semiconductor fabrication lines. Its customer base is highly diversified, and its product portfolio is extensive—comprising over 20,000 distinct SKUs—to meet the varied requirements of different industries and production lines. Over the past decade, Entegris has consistently achieved revenue growth exceeding the industry average, posting a ~12% compound annual growth rate (CAGR) in revenue. Its operating margin has likewise improved significantly—from roughly 10% earlier on to approximately 24% today. In terms of stock performance, Entegris ranks among the top-performing semiconductor stocks over the past ten years. Notably, however, the 2008 global financial crisis severely impacted Entegris: weakened demand in the semiconductor industry, combined with the company’s then-fragile market position—lacking scale and stable revenue—led to a sharp earnings decline. Consequently, its share price hit an all-time low in 2009, setting the stage for its subsequent powerful rebound. Today, Entegris holds a substantial position within the industry. Looking ahead, the company projects it can sustain a long-term annualized growth rate of approximately 15%, continuing healthy expansion through: (1) organic growth above the industry average; (2) strategic acquisitions with strong potential; and (3) expansion into new end markets. Organic growth hinges primarily on product competitiveness and underlying demand from the semiconductor industry. In terms of new-market expansion, the company is focusing especially on delivering materials and equipment solutions for the healthcare sector. Externally, much of Entegris’s historical growth has stemmed from outstanding M&A execution—numerous acquisitions have collectively built its current competitive product portfolio. The most significant recent acquisition is its purchase of Cabot Microelectronics Corporation (CCMP). CCMP is a champion in its niche within the semiconductor industry—the world leader in CMP (Chemical Mechanical Planarization) slurry, with additional capabilities in polishing pads and other electronic chemicals.

Three bearish catalysts! Seventy innovative drugs plummet collectively; AI robotics collapse; yet this sector surges.

Today is 'Black Tuesday': indices plunged across the board, and a record-breaking 5,000 individual stocks declined. Technology stocks—particularly the market’s prior leading themes—were the main drivers of this broad selloff. Behind this sharp reversal in leadership lie three major bearish catalysts—each potent enough to shift the entire market’s directional bias! First, let’s recap recent performance across key themes: Innovative pharmaceuticals: Today, 70 leading A-share innovative drug stocks fell by more than 4%; 20 of them dropped over 6%. The sector was virtually decimated—Boehringer Ingelheim’s Chinese subsidiary BoRui Pharma plunged 9%, Tibet Pharmaceutical fell 9%, Foyuan Pharmaceutical dropped 7.4%, Medisec plunged 7%, and Zhaoyan New Drug fell 7%. Next, humanoid robotics: This segment fared even worse—120 stocks declined over 4%, and 18 fell more than 6%. Yunnan Tourism plunged 10%, Shenglan Shares dropped 8%, China Electronics Port fell 7.6%, Qiangrui Technology fell 7.6%, Shida Group plunged 7.4%, and Rifeng Precision Machinery fell 7.14%. Numerous high-profile names exhibited steep ‘A-shaped’ declines—a pattern notorious for its severity, bearing hallmarks of aggressive, ‘one-stroke soul-severing’ selling pressure. Finally, the hottest AI sector: AI stocks collapsed dramatically—170 names fell over 5%, including 26 that plunged more than 7%. Kaipu Cloud tumbled 13%, HuiZhong Co., Ltd. fell 10%, Wangda Software dropped 10%, Nanfang Lujī fell 10%, Electronic City fell 9.8%, and Sudawei Ge plunged 8%. Virtually every thematic hotspot suffered heavy losses. Amid this widespread collapse of former market leaders, one sector surged unexpectedly: banking. Early this morning, the banking index rose sharply—even Industrial and Commercial Bank of China (ICBC) experienced a near-vertical rally. So far, 35 out of 42 listed banks are trading higher: Nanjing Bank surged 4%, Xiamen Bank rose 3.7%, Agricultural Bank of China climbed 3.4%, China Construction Bank gained 3.3%, and ICBC rose 2.9%.